In Vitro Susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum Isolates to 30 Antibiotics

Shen, Yaojie; Wang, Xuyang; Jin, Jialin; Wu, Jing; Zhang, Xuelian; Chen, Jiazhen; Zhang, Wenhong

doi:10.1155/2018/4902941

Cited by 62 publications

(56 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study found that 2/3 (66.6%) of M. fortiutum isolates were susceptible to CIP, and all the isolates (3/3) were resistant to the remaining tested drugs. In the recent year, a research study reported from China indicated that all M. fortiutum (17/17) isolates were extremely resistant to RIF, INH, and EMB (28), which is consistent with the results of this study. Other previous studies reported that M. fortuitum isolates were susceptible to CIP and AMK at variable MIC ranges.…”

Section: Patient Characteristics and Clinical Featuressupporting

confidence: 91%

Incidence, Clinical Manifestation, Treatment Outcome, and Drug Susceptibility Pattern of Nontuberculous Mycobacteria in HIV Patients in Tehran, Iran

Feysia

Hasan-Nejad

Amini

et al. 2020

Ethiop J Health Sci

View full text Add to dashboard Cite

BACKGROUND: Nontuberculous mycobacterial (NTM) infections have radically increased worldwide due to the increase in HIV infections. The disease activity increases with progressive immunodeficiency.METHODS: A total of 216 HIV seropositive patients suspected of having mycobacterial infection were recruited for this study. Clinical samples were collected from each patient and cultured on Lowenstein-Jensen media. Detection and species identification were simultaneously done using Reverse Blot Hybridization Assay System. Also, the minimum inhibitory concentrations (MIC) for each isolate were determined in 7H9 broth media for 10 antibiotics.RESULTS: In this study, 4 rapid and 4 slow-growing NTM species were isolated and identified. Mycobacterium fortuitum was the most common NTM species, 3/8 (37.5%), followed by Mycobacterium kansasii, 2/8 (25%). The cases were identified as pulmonary disease, 5/8 (62.5 %), disseminated infection, 2/8 (25%), and skin abscess, 1/8 (12.5%). M. chelonae and Mycobacterium avium were isolated from patients diagnosed with disseminated infection with treatment failure. The skin abscess was caused by infection with M. simiae. The results of the MIC testing were as follows: M. kansasii and M. fortuitum were susceptible to amikacin (AMK); M. avium to clarithromycin (CLA); M. fortuitum 2/3 (67%) to ciprofloxacin (CIP); 1/2 (50%) of M. kansasii isolates to CLA, and M.chelonae to rifampin (RIF), linezolid (LIN), AMK, and CIP atmedium and high concentrations.CONCLUSION: AMK showed incredible in vitro activity against M. kansasii and M. fortuitum. Also, M. avium was susceptible to CLA, whereas M. simiae and M. chelonae were resistant to the tested drugs in this study.

show abstract

Section: Patient Characteristics and Clinical Featuressupporting

confidence: 91%

Incidence, Clinical Manifestation, Treatment Outcome, and Drug Susceptibility Pattern of Nontuberculous Mycobacteria in HIV Patients in Tehran, Iran

Feysia

Hasan-Nejad

Amini

et al. 2020

Ethiop J Health Sci

View full text Add to dashboard Cite

show abstract

“…It was 40.9% in our study, which was in agreement with the rates reported in Beijing 28 and Japan. 24 However, studies conducted in 2017 in Taiwan (61%), 23 2015 in Australia (68%), 29 and 2018 in Shanghai (65%) 30 reported higher rates of IPM resistance. Notably, the M. abscessus isolates in our study had a higher resistance rate to FOX (34.02%) than the M. abscessus strains in a study in Japan (16.7%).…”

Section: Discussionmentioning

confidence: 98%

Antimicrobial Susceptibility of Mycobacterium abscessus Complex Clinical Isolates from a Chinese Tertiary Hospital

Guo

Cao

et al. 2020

IDR

View full text Add to dashboard Cite

Introduction: Mycobacterium abscessus complex (MABC) is a group of important infectious agents that are highly associated with drug resistance, and antibiotic treatment is usually ineffective. This study investigated the characteristics of antimicrobial susceptibility of MABC isolates and the synergy between certain β-lactam combinations against MABC infection. Methods: We collected 129 MABC isolates from patients with lower respiratory tract infections and categorized them into three subspecies. The minimum inhibitory concentrations (MICs) of 15 antimicrobials for the MABC isolates were determined using commercial Sensititre RAPMYCOI MIC plates and the broth microdilution method, as recommended in the CLSI (M24-A2). In addition, the MICs of imipenem, alone and with ceftazidime and/or avibactam, were assessed in vitro for all isolates. The erm(41) and rrl genes were also sequenced. Results: The MABC isolates exhibited >80% resistance to 11 of the 15 antimicrobials. Regarding the remaining four antimicrobials, the isolates were least resistant to tigecycline (12.4%) and amikacin (3.9%), and only partially resistant to two cefoxitin (39.5%) and imipenem (40.3%). Compared with M. massiliense isolates, M. abscessus and M. bolletii isolates were more resistant to amikacin and imipenem, whereas M. abscessus was significantly less resistant to tigecycline relative to M. massiliense and M. bolletii isolates. The clarithromycin inducible resistance rate was 68.4% and 74.3% among M. bolletii and M. abscessus isolates. Furthermore, 88.7% of the M. abscessus isolates carried a T at position 28 of erm(41), which is associated with inducible clarithromycin resistance. In addition, compared to imipenem with avibactam only, the MIC 50 and MIC 90 values of imipenem after adding ceftazidime plus avibactam were decreased fourfold. Conclusion: The antimicrobial resistance rates and the characteristics of the erm(41) gene associated with inducible clarithromycin resistance were different among the three MABC subspecies. There was also synergy between imipenem and 100μg/mL ceftazidime against MABC isolates.

show abstract

“…However, they seem to be less active against RGM [11,34,35]. In contrast, bedaquiline exhibited clear inhibitory effects against various species of SGM and RGM, including MFC in different studies [11,12,17,20,33,36]. Bedaquiline has mostly been described as bacteriostatic but bactericidal activity for several MFC-strains has been reported [20,22,36].…”

Section: Discussionmentioning

confidence: 99%

“…Published treatment recommendations and guidelines are mainly based on case studies, clinical experience of experts and antimicrobial susceptibility testing [1,10]. As with all other NTM-species, MFC-isolates do generally not respond to first-line antituberculous drugs and may be naturally or secondarily resistant to several antimicrobial agents [11][12][13]. MFC-susceptibility to amikacin, fluoroquinolones, sulfonamides, imipenem, linezolid, cefoxitin, doxycycline, minocycline, and clarithromycin [1] has been reported.…”

Section: Introductionmentioning

confidence: 99%

“…MFC-susceptibility to amikacin, fluoroquinolones, sulfonamides, imipenem, linezolid, cefoxitin, doxycycline, minocycline, and clarithromycin [1] has been reported. However, there is evidence of a high variability in susceptibility to these antimicrobials among different isolates [12]. While macrolides are key drugs for treatment of NTM-related pulmonary disease, in MFCisolates macrolide resistance via an inducible erythromycin methylase gene (erm) was identified despite in vitro susceptibility.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report

et al. 2020

View full text Add to dashboard Cite

Background Mycobacterium fortuitum complex is a group of rapidly growing nontuberculous mycobacteria (NTM) associated with skin and soft-tissue infections after surgery or trauma. Treatment of NTM is challenging, due to resistance to multiple antimycobacterial agents. Bedaquiline is a diarylquinoline that inhibits mycobacterial ATP-synthase. The drug has recently been approved for the treatment of multidrug-resistant tuberculosis and evidence of its in vitro efficacy against NTM, including Mycobacterium fortuitum complex, has been published. Case presentation A 20-year-old Caucasian woman with chronic skin and soft tissue infection in the lower leg following a traffic accident in Vietnam underwent a tedious journey of healthcare visits, hospital admissions, empiric antimicrobial treatments, surgical debridement and plastic reconstruction before definite diagnosis of Mycobacterium fortuitum complex-infection was established by culture from a tissue biopsy and targeted antimycobacterial therapy was administered. Histopathological examination revealed granulomatous purulent inflammation, which strongly supported the diagnosis. Genotypic identification was performed and broth microdilution for susceptibility testing showed macrolide resistance. Five weeks of induction treatment with intravenous amikacin, imipenem / cilastin, and oral levofloxacin was administered, followed by all-oral treatment with bedaquiline combined with levofloxacin for four months, which was well-tolerated and led to persistent healing with scars but without signs of residual infection. Conclusions Bedaquiline is a promising novel agent for NTM treatment, although clinical data are limited and trials evaluating efficacy, safety, and resistance of bedaquiline are required. To our knowledge, this is the first reported case of successful in vivo use of bedaquiline for a skin and soft tissue infection caused by Mycobacterium fortuitum complex.

show abstract

In Vitro Susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum Isolates to 30 Antibiotics

Cited by 62 publications

References 40 publications

Incidence, Clinical Manifestation, Treatment Outcome, and Drug Susceptibility Pattern of Nontuberculous Mycobacteria in HIV Patients in Tehran, Iran

Incidence, Clinical Manifestation, Treatment Outcome, and Drug Susceptibility Pattern of Nontuberculous Mycobacteria in HIV Patients in Tehran, Iran

<p>Antimicrobial Susceptibility of <em>Mycobacterium abscessus</em> Complex Clinical Isolates from a Chinese Tertiary Hospital</p>

Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report

Contact Info

Product

Resources

About